General Toxicology
Traditional pre-clinical development continues to show robust growth
- Required tests and models for typical small molecules
Expanding market from biotech “cross-overs”
- Amgen, Chiron, Genentech, Biogen-Idec, - all becoming heavy in small molecule R&D
Cross selling opportunities between specialty toxicology and general toxicology
CRL has sufficient capabilities
- Redundancy at multiple sites is not an issue, as the total capacity is well utilized